Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nexalin Technology Inc. (NXL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NXL (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 45.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.94M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 149433 | Beta 4.39 | 52 Weeks Range 0.53 - 4.49 | Updated Date 04/1/2025 |
52 Weeks Range 0.53 - 4.49 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -10579.48% |
Management Effectiveness
Return on Assets (TTM) -123.41% | Return on Equity (TTM) -221.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22997899 | Price to Sales(TTM) 153.76 |
Enterprise Value 22997899 | Price to Sales(TTM) 153.76 | ||
Enterprise Value to Revenue 136.31 | Enterprise Value to EBITDA 0.02 | Shares Outstanding 13303500 | Shares Floating 10812305 |
Shares Outstanding 13303500 | Shares Floating 10812305 | ||
Percent Insiders 20.7 | Percent Institutions 2.79 |
Analyst Ratings
Rating 3 | Target Price 3 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nexalin Technology Inc.
Company Overview
History and Background
Nexalin Technology Inc. is a neurostimulation company developing and commercializing non-invasive technology to treat mental health disorders. Founded to address the limitations of existing treatments, it has focused on creating a safe and effective alternative.
Core Business Areas
- Neurostimulation Technology: Development, manufacturing, and commercialization of non-invasive neurostimulation devices.
- Mental Health Treatment: Providing a therapeutic approach for anxiety, depression, and insomnia through its proprietary neurostimulation protocols.
Leadership and Structure
The leadership team consists of experienced professionals in medical device development and commercialization. The organizational structure supports research, development, manufacturing, and sales/marketing efforts.
Top Products and Market Share
Key Offerings
- Nexalin System: A non-invasive neurostimulation device used to treat anxiety, depression, and insomnia. Market share data is limited due to the niche market and emerging stage of the company. Competitors include transcranial magnetic stimulation (TMS) devices from companies like Neuronetics (STIM) and MagVenture, and other neurostimulation technologies.
Market Dynamics
Industry Overview
The neurostimulation market is growing, driven by increasing prevalence of mental health disorders and demand for non-pharmacological treatment options.
Positioning
Nexalin Technology Inc. is positioned as a provider of innovative, non-invasive neurostimulation solutions for mental health. Its competitive advantage lies in its proprietary technology and focus on specific mental health indications.
Total Addressable Market (TAM)
The global neurostimulation market is estimated to reach billions of dollars. Nexalin is targeting a segment of this market focused on anxiety, depression and insomnia treatments. Positioning is dependent on clinical trials.
Upturn SWOT Analysis
Strengths
- Proprietary neurostimulation technology
- Non-invasive treatment approach
- Potential for reduced side effects compared to medication
- Targeting large and growing mental health market
Weaknesses
- Limited clinical data compared to established treatments
- Smaller market presence compared to larger medical device companies
- Reliance on regulatory approvals for expansion
- Need for significant capital investment
Opportunities
- Expanding clinical applications through research
- Securing partnerships with hospitals and clinics
- Gaining regulatory approvals in new markets
- Increasing awareness of non-invasive treatment options
Threats
- Competition from established neurostimulation technologies
- Potential for adverse events impacting regulatory approval
- Changes in reimbursement policies
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- Neuronetics (STIM)
- MagVenture
- Brainsway (BWAY)
Competitive Landscape
Nexalin's advantages lie in its unique waveform and approach to neurostimulation, although this is offset by the greater resources of competitors with long standing products such as TMS.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is linked to the company's market expansion
Future Projections: Projections are dependent on the success of the clinical trials
Recent Initiatives: Refer to latest news for details.
Summary
Nexalin Technology Inc. is an innovative company in the neurostimulation market, focused on treating mental health disorders. While its proprietary technology presents a competitive advantage, the company faces challenges associated with clinical data, market presence, and capital requirements. Future growth depends on securing regulatory approvals, expanding clinical applications, and increasing market awareness. The company's financial success relies on continued funding and successful commercialization efforts.
Similar Companies
BWAY
Brainsway Ltd
BWAY
Brainsway Ltd
STIM
Neuronetics Inc
STIM
Neuronetics Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimates. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexalin Technology Inc.
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO, CFO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com | ||
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.